spacer
The Healthcare Sales & Marketing Network celebrates 22 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Aspergillus 

 HSMN NewsFeed - 10 Jun 2020
F2G's Olorofim Receives Both FDA Orphan Drug Designation for Coccidioidomycosis (Valley Fever) and FDA QIDP Designation for Multiple Fungal Infections
Biopharmaceuticals FDA
 HSMN NewsFeed - 8 Jun 2020
Amplyx Pharmaceuticals Expands Executive Leadership Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 May 2020
Amplyx Pharmaceuticals Adds Pfizer and Adage to Series C Financing, Bringing Total to over 90 Million
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 14 Jun 2019
SCYNEXIS Appoints Dr. Nkechi Azie as Vice President of Clinical Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 11 Feb 2019
FDA Grants Orphan Drug Designation to Amplyx Pharmaceuticals for APX001 for Treatment of Cryptococcosis
Biopharmaceuticals FDA
 HSMN NewsFeed - 1 May 2018
SCYNEXIS's Oral SCY-078 Receives FDA QIDP and Fast Track Designations for the Treatment of VVC and Prevention of Recurrent VVC
Biopharmaceuticals FDA
 HSMN NewsFeed - 19 Mar 2018
Amplyx Pharmaceuticals Receives Fourth "Qualified Infectious Disease Product" (QIDP) Designation from the FDA for APX001
Biopharmaceuticals FDA
 HSMN NewsFeed - 2 Aug 2017
Amplyx Pharmaceuticals Raises $67 Million in Series C Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 24 May 2016
Amplyx Pharmaceuticals Appoints Paul C. Grint, M.D., to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 Feb 2016
Amplyx Pharmaceuticals Expands Management Team and Increases Its Series B Financing to $49.2 Million
Biopharmaceuticals Personnel Venture Capital
 HSMN NewsFeed - 11 Nov 2015
Amplyx Pharmaceuticals Secures $40.5 Million in Series B Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 18 Nov 2013
Merck’s New Drug Application for an Investigational Intravenous (IV) Formulation of NOXAFIL(R) (posaconazole) Receives FDA Priority Review
Biopharmaceuticals FDA Regulatory
 HSMN NewsFeed - 5 Oct 2007
Interim Results from a New Trial of CANCIDAS(R) (caspofungin acetate) in Pediatric Patients with Documented Fungal Infections
Biopharmaceuticals
 HSMN NewsFeed - 20 Mar 2007
New Cancer Practice Guidelines Recommend NOXAFIL(R) (Posaconazole) for Antifungal Prophylaxis in Certain High-Risk Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Feb 2007
Basilea Reports Positive Phase III Results for Alitretinoin
Biopharmaceuticals
 HSMN NewsFeed - 15 Feb 2007
Cepheid Acquires Sangtec Molecular Diagnostics AB
Diagnostics Mergers & Acquisitions
 HSMN NewsFeed - 25 Jan 2007
The New England Journal Of Medicine Publishes Two Landmark Studies Of NOXAFIL(R) (Posaconazole) in the Prevention of Invasive Fungal Infections
Biopharmaceuticals
 HSMN NewsFeed - 19 Dec 2006
Basilea Announces Start of Phase III Program for Isavuconazole, Its Third Investigational Drug to Reach Pivotal Trials
Biopharmaceuticals
 HSMN NewsFeed - 9 Nov 2006
Noxafil(R) (Posaconazole) Oral Suspension Approved in European Union for Prevention of Invasive Fungal Infections
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 23 Oct 2006
Schering-Plough Announces FDA Approval of NOXAFIL(R) (Posaconazole) for Treatment of Oropharyngeal Candidiasis (OPC)
Biopharmaceuticals FDA
 HSMN NewsFeed - 29 Sep 2006
New Data Confirming Broad Spectrum of Basilea's Late-Stage Antifungal, BAL8557, Presented at the ICAAC Conference
Biopharmaceuticals
 HSMN NewsFeed - 22 Sep 2006
European Union's CHMP Adopts Positive Opinion for NOXAFIL(R) (posaconazole) Oral Suspension for Prevention of Invasive Fungal Infections
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 18 Sep 2006
Schering-Plough Announces FDA Approval of NOXAFIL(R) (Posaconazole) for Prevention of Invasive Fungal Infections
Biopharmaceuticals FDA
 HSMN NewsFeed - 2 May 2006
FDA Fast Track Designation for Basilea's Novel Broad-Spectrum Water-Soluble Antifungal BAL8557
Biopharmaceuticals FDA
 HSMN NewsFeed - 14 Feb 2006
Nektar Announces That U.S. FDA Has Granted Orphan Drug Designation to the First Amphotericin B Inhalation Powder to Prevent Pulmonary Fungal Infections in Immunosuppressed Patients
Biopharmaceuticals Drug Delivery FDA
Return to NewsFeed  

 Additional items found! 12

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 12 additional stories matching:
Aspergillus
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.